Fig. 4
Summary of network meta-analysis results for PFS and OS analysis. (A) OS; (B) PFS. BSC, Best Supportive Care; OS, overall survival; PFS, progression-free survival; REDo, regorafenib dose optimization; TAS-102, trifluridine/tipiracil; TAS-BEV, TAS-102 with bevacizumab